Therapeutics News and Research

RSS

ActiveCare, Vista Therapeutics announce strategic relationship to develop Nano Biosensors for seniors

ActiveCare, Inc. and Vista Therapeutics, Inc. announced today a strategic relationship to develop Nano Biosensors for ActiveCare's products and services to be utilized by the elderly. These Biosensors will allow ActiveCare to continuously monitor specific chronic diseases commonly occurring in the elderly and thus preventively predict and avoid acute medical events. "This technology is designed to prolong and improve the quality of life of our senior population," stated James Dalton, President of ActiveCare.

18 Jun 2010

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

18 Jun 2010

Encouraging interim results from stem and regenerative cell-enriched fat grafting breast reconstruction trial

Interim results from a breast reconstruction trial show stem and regenerative cell-enriched fat grafting resulted in a high sustained rate of physician and patient satisfaction and persistent improvements in overall outcomes of the procedure at six and 12 months.

18 Jun 2010

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

18 Jun 2010

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "John et al." patent (Application No. 10/384,463), which covers methods of inhibiting mutant genes with double-stranded RNAs from 19 to 30 nucleotides in length.

18 Jun 2010

Special public meeting to spotlight stem cell-based therapies for ALS

Local scientists, health advocates and leaders from the California Institute for Regenerative Medicine will gather in San Diego June 23 for a special public meeting to spotlight a new University of California, San Diego grant to pursue novel, fast-tracked stem cell-based therapies for amyotrophic lateral sclerosis, or Lou Gehrig's disease.

18 Jun 2010

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.

18 Jun 2010

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

18 Jun 2010

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.

18 Jun 2010

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).

17 Jun 2010

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs also received appropriate measures to prevent upper-gastrointestinal problems, but the remainder did not receive adequate protection, according to a study in the June issue of Alimentary Pharmacology and Therapeutics.

17 Jun 2010

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.

17 Jun 2010

Research studies may lead to future development of cell transplant therapy for ALS

The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.

17 Jun 2010

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing.

17 Jun 2010

Repros to appeal NASDAQ for additional time to regain compliance

On June 15, 2010, Repros Therapeutics Inc. received notification from NASDAQ that it has not regained compliance with NASDAQ Listing Rule 5550(a)(2) and, unless the Company appeals NASDAQ's decision, trading of the Company's common stock will be suspended and the Company's securities will be delisted from the NASDAQ Stock Market.

17 Jun 2010

Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI

Trius Therapeutics, Inc. announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI).

16 Jun 2010

Therapeutics News and Research

ActiveCare, Vista Therapeutics announce strategic relationship to develop Nano Biosensors for seniors

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

Encouraging interim results from stem and regenerative cell-enriched fat grafting breast reconstruction trial

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Special public meeting to spotlight stem cell-based therapies for ALS

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

Research studies may lead to future development of cell transplant therapy for ALS

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

Repros to appeal NASDAQ for additional time to regain compliance

Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News